Shenzhen Chipscreen Biosciences Co., Ltd. announced on April 30, 2024 that chidamide, a self-developed oral subtype-selective histone deacetylase (HDA···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 79
On November 29, 2019, Chidamide (trade name: Epidaza), a first-in-class molecular entity independently developed by Shenzhen Chipscreen Biosciences Co···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 86
Chidamide is an oral antitumor agent classified as a histone deacetylase (HDAC) inhibitor. It is primarily indicated for the treatment of relapsed or ···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 76
Chidamide must be administered strictly in accordance with the physician's instructions. The standard regimen is oral administration twice a week ···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 77
Chidamide is a targeted antitumor drug:It is an original innovative anticancer drug indicated for specific types of cancer.It exerts a therapeutic eff···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 82
Chidamide Tablets are a prescription-only medication, primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 75
Chidamide Tablets (brand name: Epidaza) is a prescription drug that is commercially available, but only with a valid doctor’s prescription and through···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 73
The price of chidamide tablets varies depending on the region, sales channel, specification and medical insurance policy, with no fixed price per box ···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 72
The price of Chidamide varies by region, medical insurance policies and purchase channels; for specific pricing, please consult local hospitals or lic···【Read More】
Update: 2026-02-03Source: Haiou HealthViews: 73
During the administration of Chidamide Tablets, dietary restrictions should be strictly observed to reduce the risk of adverse drug reactions and enha···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 75
The price of furmonertinib is influenced by factors such as drug specifications, regional differences and medical insurance policies, with the price p···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 73
Furmonertinib (Furmonertinib Mesylate) is a third-generation EGFR-TKI inhibitor primarily indicated for the treatment of non-small cell lung cancer (N···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 77
Furmonertinib Mesylate Tablets is a third-generation EGFR-TKI inhibitor, primarily indicated for the treatment of advanced non-small cell lung cancer ···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 84
On June 29, 2022, Shanghai Acebright Pharmaceutical Technology Co., Ltd. (Stock Code: 688578) announced that Furmonertinib Mesylate (trade name: Afure···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 84
On March 3, 2021, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Furmonertinib Mesylate Tablets···【Read More】
Update: 2026-02-02Source: Haiou HealthViews: 81
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



